ebna1-specific cytotoxic t-lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01555892)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epstein-Barr nuclear antigen 1Immunity, passive
EBNA1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ebna1-specific cytotoxic t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01555892 | Phase 1 | Jan 1, 2013 | Baylor University, Methodist Cancer Center, Houston, Texas, National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1